ERBB2 and non-small cell lung carcinoma: Selective tyrosine kinase inhibitors. Non-selective pan-HER TKIs have demonstrated moderate antitumor activity, achieving sporadic responses against exon 20 insertions that represent the most common genomic aberration in HER2-mutant NSCLC.